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Abstract
This Genetic Analysis Workshop 13 contribution presents a linkage analysis of hypertension in the
Framingham data based on the posterior probability of linkage, or PPL. We dichotomized the
phenotype, coding individuals who had been treated for hypertension at any time, as well as those
with repeated high blood pressure measurements, as affected. Here we use a new variation on the
multipoint PPL that incorporates integration over the genetic model. PPLs were computed for
chromosomes 1 through 5, 11, 14, and 17 and remained below the 2% assumed prior probability
of linkage for 73% of the locations examined. The maximum PPL of 4.5% was obtained on
chromosome 1 at 178 cM. Although this is more than twice the assumed prior probability of
linkage, it is well below a level at which we would recommend committing substantial additional
resources to molecular follow-up. While the PPL analysis of this data remains inconclusive, Bayesian
methodology gives us a clear mechanism for using the information gained here in further studies.
Background
The posterior probability of linkage, or PPL, has several
advantages over other parametric methods [1]. First, it is
directly interpretable as the probability of linkage to a spe-
cific marker or location along the genome. Second, as a
Bayesian statistic, can incorporate any prior information
that the researcher might have before the outset of a study.
Third, it provides an easy way to combine the information
from several studies without pooling the data.
Here we exploit a fourth feature of the PPL, which allows
us to integrate over the parameters of the trait model,
resulting in a statistic that is model-free in the sense that it
does not fix trait parameters at specific values. Thus, we
are able to allow for heterogeneity, reduced penetrance,
and phenocopies. Additionally, using integration in this
way allows us to avoid the inflationary effects on the like-
lihood of maximizing over multiple parameters. This
makes the model-integrated PPL an ideal tool for the anal-
ysis of complex diseases such as hypertension.
This also represents the first analysis using a model-inte-
grated version of the PPL based on multipoint likeli-
hoods. The multipoint PPL gives us an indication of
whether or not there is a disease gene close to each posi-
tion on the chromosome [2], in contrast to the two-point
version [1,3-5], which estimates the probability of linkage
to each marker individually.
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Methods
Data description
When analyzing the Framingham Heart Study data set,
two issues needed attention. First, it was necessary to
establish a dichotomous phenotype definition that relia-
bly captured the information from the multiple measure-
ments. Our phenotype definition combined the "treated
for hypertension" variable and the "high blood pressure"
variable. An individual treated for hypertension at any
time point was called affected. Of those not treated for
hypertension, individuals having high blood pressure at
four or more time points were coded as affected; the
majority (57%) of people who had four or more high
blood pressure readings were also treated for hyperten-
sion at some point. Of the people who had three or fewer
high blood pressure readings, those who had fewer than
eight recorded measurements were coded as unknown.
Those with eight or more measurements were coded as
unaffected. Individuals with no history of treatment and
no blood pressure measurements were coded as
unknown. This definition was intended to minimize the
number of misclassified individuals by coding those with-
out a clear propensity for high or normal blood pressure
as unknown.
The large amounts of relatively sparse data pose a second
problem. First, 144 pedigrees with fewer than three
affected members (according to our phenotype defini-
tion) were removed. This could have the effect of elimi-
nating sporadic cases, resulting in a more homogeneous
data set, but primarily this was done to speed the calcula-
tions. Of the remaining 190 pedigrees, GENEHUNTER
[see below] was unable to use 60 due to their structure.
Therefore, we split these pedigrees into their constituent
nuclear families using MEGA2 (Version 2.3, http://
watson.hgen.pitt.edu[6]). (See [7] for potential pitfalls.)
The final data set was made up of 620 pedigrees, with an
average pedigree size of 5.96. Of the 3695 individuals in
the data set, 1312 were coded as affected, 232 were coded
as unaffected, and the remaining 2151 were coded as
unknown.
Due to the computational complexity of the methods,
eight chromosomes were chosen for analysis. PPLs are
presented for chromosomes 1 through 5, 11, 14, and 17.
Statistical methods
The statistical methods used in this paper are a logical
extension of previous work on the PPL. Initially, the PPL
was developed as a two-point statistic based on a hetero-
geneity LOD score [1,4-6]. In the Genetic Analysis Work-
shop 12 this was expanded to include a multipoint
version [2]. Recently the two-point PPL has been adapted
to allow integration over the parameters of the genetic
model [8], and used in a genome screen for specific lan-
guage impairment [9]. In this paper we have combined
these two variants to produce a multipoint version of the
model-integrated PPL. The model integrated multipoint
PPL at position t0 can be written:
where t is the cM position; PL is the assumed prior proba-
bility of linkage; k is the size of the moving window (see
below); α is the admixture parameter [10]; and g is a vec-
tor of parameters that describe the genetic model (disease
allele frequency and three penetrances). The HLOD is the
multipoint heterogeneity (admixture) LOD score [11] as a
function of t, α and g. The prior distributions for g and α
are represented by h(g) and h(α).
The moving-window prior h(|t - t0|) on the disease gene
location is used to summarize the probability that a risk
locus is close to each position. This prior is constructed to
mirror the one used in the two-point case, and places pos-
itive probability at all points within 44 cM, with 95% of
the probability concentrated within ± 5 cM [2].
Multipoint LOD scores are computed by a series of pro-
grams that make repeated calls to GENEHUNTER [12],
varying the values of the genetic model in each run.
HLODs are computed every cM at 20 different α values for
1650 different genetic models (see [9] for a complete
description of the model grid). The average likelihood
ratio (10HLOD(t,  α,  g)) is computed at each position to
approximate the integration of the likelihood surface over
the genetic model. A 2% prior probability was assumed
[13].
Results
73% of the PPLs were below the prior probability of link-
age. The maximum PPL of 4.5% was observed on chromo-
some 1 at 178 cM. The next highest PPL of 4.2% was
achieved on chromosome 3 at 135 cM. The PPL was below
4% on the remaining chromosomes. The graphs of the
PPLs for chromosomes 1 through 5, 11, 14, and 17 are
presented in Figure 1.
Conclusions
At this point we have no compelling evidence for a hyper-
tension-predisposing gene on any of the chromosomes
we examined. Our largest PPLs of 4.5% and 4.2% were
observed on chromosomes 1 and 3. A PPL of 4% indicates
a location that is twice as likely to be linked to the trait
being studied than one chosen at random. However, this
is well below the level at which we would suggest commit-
ting substantial additional resources to fine mapping or
molecular work.
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Chromosome PPLs Figure 1
Chromosome PPLs. A, chromosome 1; B, chromosome 2;C, chromosome 3; D, chromosome 4; E, chromosome 5; F, chromo-
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Overall, PPLs obtained do not differ much from the
assumed prior probability of linkage. This indicates that
we have little evidence for or against linkage across the
genome. The PPL has the property that as the amount of
genetic information increases the PPL converges to 1
under linkage and 0 under no linkage [4]. One explana-
tion for this is a lack of sufficient data. Further work with
this data set could involve performing the analysis using a
program other than GENEHUNTER, which was chosen
for computational convenience. It has been shown that
the pedigree trimming performed by GENEHUNTER and
the splitting of pedigrees into nuclear families can cause
low power and misleading results [7]. Furthermore, as
additional data become available, the Bayesian nature of
the PPL yields a natural way to update the information
from one study to the next. The posterior distributions
computed in this analysis could be used as the prior infor-
mation for further studies of hypertension. Alternatively,
our definition of the phenotype may not be genetically
relevant.
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